Michael B.
- Country
- Denmark
- Department
- Department of Urology, Palle Juul Jensens Boulevard 99, 8200 Aarhus N
Research Overview
- Open-Label Extension Study on Long-Term Safety of Enzalutamide in Prostate Cancer Patients from Previous Clinical Trials
- Evaluation of Atorvastatin on Progression of Metastatic or High-Risk Recurrent Prostate Cancer During Androgen Deprivation Therapy: A Phase 3 Randomized Controlled Trial
- Evaluation of Apalutamide Addition to Radiotherapy and LHRH Agonist in High-Risk Hormone-Sensitive Prostate Cancer Assessed by PSMA-PET
Data & Insights
Has run more than one trial at 73 of 225 partner sites.
Specializations
Advanced Prostate Cancer Treatment
This investigator specializes in studying innovative therapeutic approaches for advanced prostate cancer, with particular focus on hormone-sensitive prostate cancer and biochemically recurrent disease.
- Androgen Deprivation Therapy (ADT) Combinations
- Novel Antiandrogen Treatments
- High-Risk Disease Management
Expertise in evaluating therapeutic combinations including darolutamide and enzalutamide with ADT.
Innovative Treatment Strategies
Focus on developing treatment protocols incorporating radiotherapy and various therapeutic agents for high-risk prostate cancer patients.
- PSMA-PET Guided Treatment
- Combined Modality Approaches
- Post-Prostatectomy Therapy
Specializes in evaluating apalutamide and other novel therapeutic combinations.
Alternative Treatment Pathways
Investigation of non-traditional approaches including statin therapy in prostate cancer management, particularly focusing on disease progression prevention.
- Metabolic Intervention Studies
- Long-term Treatment Outcomes
- Castration Resistance Prevention
Explores the role of atorvastatin in modifying cancer progression during hormone therapy.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.